Skip to content

The Relationship Between Fatty Liver and Breast Cancer

The Relationship Between Fatty Liver and Breast Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06402084
Enrollment
100
Registered
2024-05-07
Start date
2024-05-02
Completion date
2025-05-05
Last updated
2024-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The Relationship Between Fatty Liver and Breast Cancer

Brief summary

clinicopathological result of a common is (NAFLD) alcoholic fatty liver disease-nNo 30% of -NAFLD affects 20% .not caused by alcohol intake is chronic liver disease thatsuch as conditions spectrum of population and can be characterized by wide general et Chalasani( steatosis by isolated intracellular fat deposition marked noninflammatory .al., 2012) homeostasis and egulation of hepatic cholesterol NAFLD occurs due to the dysr . NAFLD is liver in triglycerides and free cholesterol, free fatty acids, accumulation ofabdominal and with insulin resistance, diabetes mellitus, metabolic syndrome associatedimplicated in the be can NAFLD that suggested reports the arge number ofL .obesity kidney diseases as well as cancersf cardiovascular, pulmonary, and pathology o .2015) et al., (Arguello their course of the Patients with breast cancer commonly develop NAFLD during .45.2%-2.3% approximately cancer is disease. The incidence of NAFLD in breast by influenced metabolic profile and is patient's NAFLD seems to be associated with cardiovascular and resistance insulin causingand treatment, breast cancer complications (Lee et al., 2017). modulators term estrogen inhibition with selective estrogen receptors-Long liver with tamoxifen fatty incidence of The s been reported to cause NAFLD.ha (SERMs)of NAFLD development in impact heT . use an that for aromatase inhibitoruse is higher th et al., (Yang breast cancer patients after hormonal treatment has not yet been elucidated .)6201 main and is aworldwide most common cancer in womenBreast cancer is the decreasing with has been cancer breast from ityortalM .women in death cancer of causeIt is well known time given the advances in screening strategies and adjuvant treatments. incidence of breast cancer is correlated with age and other risk factors such asthat the mutation, family history of )BRCA2( breast cancer gene2 or )BRCA1(gene1breast cancer al.,et Berry( and hormonal factors chest the to breast cancer, therapeutic radiation5).200 Breast cancer is divided according to the hormone receptors into either hormone receptor-positive tumors which are estrogen receptor-positive (ER-positive) and progesterone receptor-positive (PR-positive). These tumors express hormone receptors. This means they have a lot of hormone receptors. Hormone receptor-negative tumors are estrogen receptor-negative (ER-negative) and progesterone receptor-negative (PR-negative). These tumors donot express hormone receptors. This means they have few or no hormone receptors. About 70% to 80% of newly diagnosed breast cancers are hormone receptor- .al., 2017) (Wang et positive

Interventions

DIAGNOSTIC_TESTabdominal ultrasound

abdominal ultrasound and lipid profile will be done

Sponsors

Samar Saad Abdelrahman
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years

Inclusion criteria

* 65 years old)-Age (18-1 performance (PS0;full active,noPerformance status \< or equal to 2 Patients with-2PS1;strenuous physical activity restricted,fully ambulatory and able to ----restriction.care but unable to carry out any work -PS2;capable of all self-------carry out light work.activities up and about \>50% of woking hours)

Exclusion criteria

* Patients who had double malignancy.-1 Patients who had severe comorbidities -2 heart failure…..etc,)(pulmonary failure,Renal failure, Those who declined cancer treatment before completing 85% of the planned dosage -3 hose who are lost during the follow up period.tor

Design outcomes

Primary

MeasureTime frameDescription
lipid profile in patients with breast cancer1 yearThe relationship between Fatty Liver and Breast Cancer by abdominal ultrasound and lipid

Countries

Egypt

Contacts

Primary Contactsamar S Abd El-Rahman, resident
samar.saad@med.sohag.edu.eg01157685509
Backup ContactMahmoud S Abdel Fattah, professor
01091055908

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026